

# Elena E Balashova

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4940085/publications.pdf>

Version: 2024-02-01

34  
papers

468  
citations

687220

13  
h-index

752573

20  
g-index

34  
all docs

34  
docs citations

34  
times ranked

467  
citing authors

#	ARTICLE	IF	CITATIONS
1	Changing Landscape of Cancer Vaccines—Novel Proteomics Platform for New Antigen Compositions. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4401.	1.8	2
2	Mass spectrometry-based metabolomics diagnostics —“ myth or reality?. <i>Expert Review of Proteomics</i> , 2021, 18, 7-12.	1.3	21
3	Antigenic Essence: Upgrade of Cellular Cancer Vaccines. <i>Cancers</i> , 2021, 13, 774.	1.7	6
4	Metabolomic Laboratory-Developed Tests: Current Status and Perspectives. <i>Metabolites</i> , 2021, 11, 423.	1.3	16
5	Personal Metabolomics: A Global Challenge. <i>Metabolites</i> , 2021, 11, 715.	1.3	4
6	Holistic Metabolomic Laboratory-Developed Test (LDT): Development and Use for the Diagnosis of Early-Stage Parkinson—™s Disease. <i>Metabolites</i> , 2021, 11, 14.	1.3	4
7	Comparative Metabolomic Study of <i>Drosophila</i> Species with Different Lifespans. <i>International Journal of Molecular Sciences</i> , 2021, 22, 12873.	1.8	4
8	In Situ Mass Spectrometry Diagnostics of Impaired Glucose Tolerance Using Label-Free Metabolomic Signature. <i>Diagnostics</i> , 2020, 10, 1052.	1.3	0
9	Metabolomics Community in Russia: History of Development, Key Participants, and Results. <i>BioTech</i> , 2020, 9, 20.	1.3	0
10	Diagnosis of Parkinson—™s Disease by A Metabolomics-Based Laboratory-Developed Test (LDT). <i>Diagnostics</i> , 2020, 10, 332.	1.3	13
11	Parkinson—™s Disease: Available Clinical and Promising Omics Tests for Diagnostics, Disease Risk Assessment, and Pharmacotherapy Personalization. <i>Diagnostics</i> , 2020, 10, 339.	1.3	20
12	Mass Spectrometry-Based Metabolomics Analysis of Obese Patients—™ Blood Plasma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 568.	1.8	23
13	Metabolomics-based Approach to Pharmacotherapy Personalization: Advantages and Limitations. <i>Current Pharmacogenomics and Personalized Medicine</i> , 2019, 16, 192-198.	0.2	4
14	Metabolomic diagnostics and human digital image. <i>Personalized Medicine</i> , 2019, 16, 133-144.	0.8	10
15	SANTAVACTM: Summary of Research and Development. <i>Vaccines</i> , 2019, 7, 186.	2.1	5
16	Evaluation of Dried Blood Spot Sampling for Clinical Metabolomics: Effects of Different Papers and Sample Storage Stability. <i>Metabolites</i> , 2019, 9, 277.	1.3	34
17	n-Butylamine for Improving the Efficiency of Untargeted Mass Spectrometry Analysis of Plasma Metabolite Composition. <i>International Journal of Molecular Sciences</i> , 2019, 20, 5957.	1.8	7
18	A Metabolomics Approach to Pharmacotherapy Personalization. <i>Journal of Personalized Medicine</i> , 2018, 8, 28.	1.1	54

#	ARTICLE	IF	CITATIONS
19	Plasma Metabolome Signature in Patients with Early-stage Parkinson Disease. <i>Current Metabolomics</i> , 2018, 6, .	0.5	17
20	Label-free data standardization for clinical metabolomics. <i>BioData Mining</i> , 2017, 10, 10.	2.2	11
21	SANTAVAC $\hat{a}, \hat{c}$ : A Novel Universal Antigen Composition for Developing Cancer Vaccines. <i>Recent Patents on Biotechnology</i> , 2017, 11, 32-41.	0.4	2
22	Allogeneic Antigen Composition for Preparing Universal Cancer Vaccines. <i>Journal of Immunology Research</i> , 2016, 2016, 1-7.	0.9	5
23	Mass spectrometric signatures of the blood plasma metabolome for disease diagnostics. <i>Biomedical Reports</i> , 2016, 4, 122-126.	0.9	23
24	Design of universal cancer vaccines using natural tumor vessel-specific antigens (SANTAVAC). <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 689-698.	1.4	13
25	Prediction of classical clinical chemistry parameters using a direct infusion mass spectrometry. <i>International Journal of Mass Spectrometry</i> , 2015, 388, 53-58.	0.7	6
26	Diagnosing Impaired Glucose Tolerance Using Direct Infusion Mass Spectrometry of Blood Plasma. <i>PLoS ONE</i> , 2014, 9, e105343.	1.1	27
27	Tumor-induced endothelial cell surface heterogeneity directly affects endothelial cell escape from a cell-mediated immune response in vitro. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 198-209.	1.4	12
28	Universal cancer vaccine. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1549-1552.	1.4	8
29	Proteomic Footprinting of Drug-Treated Cancer Cells as a Measure of Cellular Vaccine Efficacy for the Prevention of Cancer Recurrence. <i>Molecular and Cellular Proteomics</i> , 2012, 11, M111.014480.	2.5	15
30	Cellular Cancer Vaccines: an Update on the Development of Vaccines Generated from Cell Surface Antigens. <i>Journal of Cancer</i> , 2010, 1, 230-241.	1.2	49
31	Proteolytically-cleaved Fragments of Cell Surface Proteins Stimulate a Cytotoxic Immune Response Against Tumor-activated Endothelial Cells In vitro. <i>Journal of Cancer Science &amp; Therapy</i> , 2010, 02, 126-131.	1.7	15
32	Proteolytically-cleaved Fragments of Cell-surface Proteins from Live Tumor Cells Stimulate Anti-tumor Immune Response In vitro. <i>Journal of Carcinogenesis &amp; Mutagenesis</i> , 2010, 01, .	0.3	12
33	Cell proteomic footprint. <i>Rapid Communications in Mass Spectrometry</i> , 2009, 23, 680-682.	0.7	19
34	Detection of the centriole tyr- or acet-tubulin changes in endothelial cells treated with thrombin using microscopic immunocytochemistry. <i>Cytoskeleton</i> , 2005, 62, 1-12.	4.4	7